

Amanda Mocroft

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1588617/publications.pdf>

Version: 2024-02-01

304
papers

18,439
citations

14653

66
h-index

15730

125
g-index

309
all docs

309
docs citations

309
times ranked

11468
citing authors

#	ARTICLE	IF	CITATIONS
1	Changing patterns of mortality across Europe in patients infected with HIV-1. <i>Lancet, The</i> , 1998, 352, 1725-1730.	13.7	1,182
2	Decline in the AIDS and death rates in the EuroSIDA study: an observational study. <i>Lancet, The</i> , 2003, 362, 22-29.	13.7	1,157
3	Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. <i>Aids</i> , 2005, 19, 593-601.	2.2	472
4	AIDS across Europe, 1994-1998: the EuroSIDA study. <i>Lancet, The</i> , 2000, 356, 291-296.	13.7	431
5	Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. <i>Lancet, The</i> , 2001, 357, 592-598.	13.7	403
6	Late presentation of HIV infection: a consensus definition. <i>HIV Medicine</i> , 2011, 12, 61-64.	2.2	378
7	Influence of Hepatitis C Virus Infection on HIV-1 Disease Progression and Response to Highly Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2005, 192, 992-1002.	4.0	362
8	Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. <i>Aids</i> , 2010, 24, 1667-1678.	2.2	353
9	Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. <i>Aids</i> , 1999, 13, 943-950.	2.2	335
10	Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. <i>Aids</i> , 2001, 15, 1261-1268.	2.2	286
11	Changing incidence of central nervous system diseases in the EuroSIDA cohort. <i>Annals of Neurology</i> , 2004, 55, 320-328.	5.3	273
12	Association Between Antiretroviral Exposure and Renal Impairment Among HIV-Positive Persons With Normal Baseline Renal Function: the D:A:D Study. <i>Journal of Infectious Diseases</i> , 2013, 207, 1359-1369.	4.0	271
13	Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. <i>Aids</i> , 2002, 16, 1663-1671.	2.2	259
14	Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). <i>PLoS Medicine</i> , 2013, 10, e1001510.	8.4	256
15	Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 262-270.	2.1	243
16	Predictors of Virological Success and Ensuing Failure in HIV-Positive Patients Starting Highly Active Antiretroviral Therapy in Europe. <i>Archives of Internal Medicine</i> , 2000, 160, 1123.	3.8	220
17	Influence of Age on CD4 Cell Recovery in Human Immunodeficiency Virus-Infected Patients Receiving Highly Active Antiretroviral Therapy: Evidence from the EuroSIDA Study. <i>Journal of Infectious Diseases</i> , 2001, 183, 1290-1294.	4.0	219
18	Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. <i>Lancet, The</i> , 2007, 370, 407-413.	13.7	217

#	ARTICLE	IF	CITATIONS
19	All-cause mortality in treated HIV-infected adults with CD4 >=500/mm ³ compared with the general population: evidence from a large European observational cohort collaboration. <i>International Journal of Epidemiology</i> , 2012, 41, 433-445.	1.9	217
20	Discontinuation of <i>Pneumocystis carinii</i> pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. <i>Lancet</i> , The, 1999, 353, 1293-1298.	13.7	206
21	Chronic renal failure among HIV-1-infected patients. <i>Aids</i> , 2007, 21, 1119-1127.	2.2	192
22	Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. <i>Aids</i> , 2001, 15, 185-194.	2.2	187
23	An internationally generalizable risk index for mortality after one year of antiretroviral therapy. <i>Aids</i> , 2013, 27, 563-572.	2.2	170
24	Increased number of primed activated CD8+CD38+CD45RO+T cells predict the decline of CD4+T cells in HIV-1-infected patients. <i>Aids</i> , 1996, 10, 827-834.	2.2	168
25	Relations among CD4 Lymphocyte Count Nadir, Antiretroviral Therapy, and HIV-1 Disease Progression: Results from the EuroSIDA Study. <i>Annals of Internal Medicine</i> , 1999, 130, 570.	3.9	157
26	Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. <i>Aids</i> , 2011, 25, 1305-1315.	2.2	157
27	Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. <i>Lancet HIV</i> , the, 2016, 3, e23-e32.	4.7	157
28	Discontinuation of Secondary Prophylaxis against <i>Pneumocystis carinii</i> Pneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral Therapy. <i>New England Journal of Medicine</i> , 2001, 344, 168-174.	27.0	155
29	Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. <i>Aids</i> , 2010, 24, 697-706.	2.2	150
30	Spontaneous Viral Clearance, Viral Load, and Genotype Distribution of Hepatitis C Virus (HCV) in HIV-Infected Patients with Anti-HCV Antibodies in Europe. <i>Journal of Infectious Diseases</i> , 2008, 198, 1337-1344.	4.0	145
31	Feasibility and Effectiveness of Indicator Condition-Guided Testing for HIV: Results from HIDES I (HIV) Tj ETQq1 1 0.784314 rgBT /Ove 2.5 145	2.5	145
32	Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. <i>Aids</i> , 1998, 12, 2161-2167.	2.2	142
33	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. <i>Clinical Infectious Diseases</i> , 2014, 58, 1312-1321.	5.8	140
34	Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2014, 59, 287-297.	5.8	136
35	The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003. <i>Cancer</i> , 2004, 100, 2644-2654.	4.1	132
36	The Coding Causes of Death in HIV (CoDe) Project. <i>Epidemiology</i> , 2011, 22, 516-523.	2.7	129

#	ARTICLE	IF	CITATIONS
37	Infections with <i>Mycobacterium tuberculosis</i> and <i>Mycobacterium avium</i> among HIV-infected Patients after the Introduction of Highly Active Antiretroviral Therapy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 162, 865-872.	5.6	124
38	A Comparison of Exposure Groups in the EuroSIDA Study: Starting Highly Active Antiretroviral Therapy (HAART), Response to HAART, and Survival. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 1999, 22, 369.	2.1	122
39	Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. <i>Cancer</i> , 2010, 116, 5306-5315.	4.1	120
40	Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study. <i>PLoS Medicine</i> , 2015, 12, e1001809.	8.4	119
41	A Clinically Prognostic Scoring System for Patients Receiving Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study. <i>Journal of Infectious Diseases</i> , 2002, 185, 178-187.	4.0	116
42	CD8+, CD38+ Lymphocyte Percent. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1997, 14, 158-162.	0.3	111
43	Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?. <i>Aids</i> , 2005, 19, 2117-2125.	2.2	109
44	Variable Impact on Mortality of AIDS-Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS-Defining Conditions Are Created Equal. <i>Clinical Infectious Diseases</i> , 2009, 48, 1138-1151.	5.8	108
45	Reduced bone mineral density in HIV-positive individuals. <i>Aids</i> , 2001, 15, 1731-1733.	2.2	107
46	Virological rebound after suppression on highly active antiretroviral therapy. <i>Aids</i> , 2003, 17, 1741-1751.	2.2	99
47	HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T-cell lymphocytes. <i>Blood</i> , 2011, 117, 6100-6108.	1.4	99
48	Tuberculosis after Initiation of Antiretroviral Therapy in Low-Income and High-Income Countries. <i>Clinical Infectious Diseases</i> , 2007, 45, 1518-1521.	5.8	98
49	Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. <i>Aids</i> , 1996, 10, 1101-5.	2.2	97
50	Is It Safe to Discontinue Primary <i>Pneumocystis jirovecii</i> Pneumonia Prophylaxis in Patients with Virologically Suppressed HIV Infection and a CD4 Cell Count ≥ 200 Cells/ μ L?. <i>Clinical Infectious Diseases</i> , 2010, 51, 611-619.	5.8	96
51	Are There Gender Differences in Starting Protease Inhibitors, HAART, and Disease Progression Despite Equal Access to Care?. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000, 24, 475-482.	2.1	95
52	Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy. <i>Aids</i> , 1999, 13, 1203-1206.	2.2	93
53	Incidence and Risk Factors of HIV-Related Non-Hodgkin's Lymphoma in the era of Combination Antiretroviral Therapy: A European Multicohort Study. <i>Antiviral Therapy</i> , 2009, 14, 1065-1074.	1.0	92
54	The Incidence of AIDS-Defining Illnesses at a Current CD4 Count ≥ 200 Cells/ μ L in the Post-Combination Antiretroviral Therapy Era. <i>Clinical Infectious Diseases</i> , 2013, 57, 1038-1047.	5.8	92

#	ARTICLE	IF	CITATIONS
55	Loss to follow-up in an international, multicentre observational study. <i>HIV Medicine</i> , 2008, 9, 261-269.	2.2	91
56	Are There Gender Differences in Starting Protease Inhibitors, HAART, and Disease Progression Despite Equal Access to Care?. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000, 24, 475-482.	2.1	89
57	Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort. <i>Aids</i> , 2018, 32, 2405-2416.	2.2	83
58	Death rates in HIV-positive antiretroviral-naïve patients with CD4 count greater than 350 cells per μ L in Europe and North America: a pooled cohort observational study. <i>Lancet</i> , The, 2010, 376, 340-345.	13.7	82
59	Time to Virological Failure of 3 Classes of Antiretrovirals after Initiation of Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study Group. <i>Journal of Infectious Diseases</i> , 2004, 190, 1947-1956.	4.0	80
60	Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. <i>Aids</i> , 2000, 14, 1545-1552.	2.2	79
61	Higher Risk of Abdominal Obesity, Elevated Low-Density Lipoprotein Cholesterol, and Hypertriglyceridemia, but not of Hypertension, in People Living With Human Immunodeficiency Virus (HIV): Results From the Copenhagen Comorbidity in HIV Infection Study. <i>Clinical Infectious Diseases</i> , 2018, 67, 579-586.	5.8	73
62	Lower prevalence and incidence of HIV-1 syncytium-inducing phenotype among injecting drug users relative to homosexual men. <i>Aids</i> , 1996, 10, 344.	2.2	71
63	Factors Associated with the Development of Opportunistic Infections in HIV-1 Infected Adults with High CD4+Cell Counts: A EuroSIDA Study. <i>Journal of Infectious Diseases</i> , 2006, 194, 633-641.	4.0	70
64	Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. <i>Eurosurveillance</i> , 2015, 20, .	7.0	70
65	Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. <i>International Journal of Epidemiology</i> , 1997, 26, 400-407.	1.9	69
66	Reasons for Stopping Antiretrovirals Used in an Initial Highly Active Antiretroviral Regimen: Increased Incidence of Stopping due to Toxicity or Patient/Physician Choice in Patients with Hepatitis C Coinfection. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 743-752.	1.1	69
67	Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. <i>Aids</i> , 2009, 23, 1689-1699.	2.2	69
68	Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. <i>HIV Medicine</i> , 2007, 8, 96-104.	2.2	68
69	Health-Related Quality of Life in Individuals Infected with HIV in the Era of HAART. <i>HIV Clinical Trials</i> , 2001, 2, 484-492.	2.0	66
70	Hepatitis B and C Co-Infection Are Independent Predictors of Progressive Kidney Disease in HIV-Positive, Antiretroviral-Treated Adults. <i>PLoS ONE</i> , 2012, 7, e40245.	2.5	66
71	Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort. <i>Clinical Infectious Diseases</i> , 2017, 64, 1413-1421.	5.8	66
72	Prognostic Importance of Anaemia in HIV Type-1-Infected Patients Starting Antiretroviral Therapy: Collaborative Analysis of Prospective Cohort Studies. <i>Antiviral Therapy</i> , 2008, 13, 959-967.	1.0	65

#	ARTICLE	IF	CITATIONS
73	The surgical management of women with ovarian cancer in the south west of England. <i>British Journal of Cancer</i> , 2001, 85, 1824-1830.	6.4	64
74	Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. <i>Aids</i> , 2009, 23, 2029-2037.	2.2	64
75	Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). <i>International Journal of Epidemiology</i> , 2014, 43, 691-702.	1.9	64
76	The Incidence of AIDS-Defining Illnesses in 4883 Patients With Human Immunodeficiency Virus Infection. <i>Archives of Internal Medicine</i> , 1998, 158, 491.	3.8	62
77	Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe: a EuroSIDA study, 1994-2001. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2004, 23, 550-9.	2.9	62
78	Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. <i>Aids</i> , 2012, 26, 1917-1926.	2.2	62
79	Medical and Societal Consequences of Late Presentation. <i>Antiviral Therapy</i> , 2010, 15, 9-15.	1.0	61
80	Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. <i>Aids</i> , 2014, 28, 187-199.	2.2	60
81	Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. <i>Aids</i> , 2010, 24, 857-865.	2.2	59
82	Gender Differences in Virologic Response to Treatment in an HIV-Positive Population: A Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 26, 159-163.	2.1	58
83	Predictors of Immunological Failure after Initial Response to Highly Active Antiretroviral Therapy in HIV-Infected Adults: A EuroSIDA Study. <i>Journal of Infectious Diseases</i> , 2004, 190, 148-155.	4.0	58
84	Airflow limitation in people living with HIV and matched uninfected controls. <i>Thorax</i> , 2018, 73, 431-438.	5.6	57
85	Opportunistic Disease and Mortality in Patients Coinfected with Hepatitis B or C Virus in the Strategic Management of Antiretroviral Therapy (SMART) Study. <i>Clinical Infectious Diseases</i> , 2008, 47, 1468-1475.	5.8	53
86	Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study. <i>Lancet HIV</i> , 2016, 3, e120-e131.	4.7	53
87	Changes in AIDS-Defining Illnesses in a London Clinic, 1987-1998. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 1999, 21, 401.	2.1	52
88	Association of Virus Load, CD4 Cell Count, and Treatment with Clinical Progression in Human Immunodeficiency Virus-Infected Patients with Very Low CD4 Cell Counts. <i>Journal of Infectious Diseases</i> , 2002, 186, 189-197.	4.0	52
89	Changes in hospital admissions across Europe: 1995-2003. Results from the EuroSIDA study. <i>HIV Medicine</i> , 2004, 5, 437-447.	2.2	52
90	HIV-1 Subtypes and Response to Combination Antiretroviral Therapy in Europe. <i>Antiviral Therapy</i> , 2006, 11, 707-716.	1.0	52

#	ARTICLE	IF	CITATIONS
91	Changes in use of antiretroviral therapy in regions of Europe over time. <i>Aids</i> , 1998, 12, 2031-2039.	2.2	51
92	Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 548-555.	3.0	51
93	Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata. <i>Aids</i> , 2011, 25, 2259-2268.	2.2	51
94	Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. <i>Aids</i> , 2016, 30, 1731-1743.	2.2	50
95	Survival after diagnosis of AIDS: a prospective observational study of 2625 patients. <i>BMJ: British Medical Journal</i> , 1997, 314, 409-409.	2.3	50
96	Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. <i>Antiviral Therapy</i> , 2008, 13, 959-67.	1.0	50
97	Hepatitis C Virus Coinfection Does Not Influence the CD4 Cell Recovery in HIV-1-Infected Patients With Maximum Virologic Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 50, 457-463.	2.1	49
98	The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study. <i>Aids</i> , 2001, 15, 201-209.	2.2	48
99	Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study. <i>Clinical Infectious Diseases</i> , 2016, 63, 821-829.	5.8	48
100	Interruption of antiretroviral therapy is associated with increased plasma cystatin C. <i>Aids</i> , 2009, 23, 71-82.	2.2	47
101	The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. <i>Aids</i> , 1999, 13, 1255-1261.	2.2	46
102	Anemia and Survival in Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2003, 37, S297-S303.	5.8	46
103	Transmitted Drug Resistant HIV-1 and Association With Virologic and CD4 Cell Count Response to Combination Antiretroviral Therapy in the EuroSIDA Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 48, 324-333.	2.1	46
104	Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. <i>HIV Medicine</i> , 2013, 14, 614-623.	2.2	46
105	Liver-related death among HIV/hepatitis C virus-co-infected individuals. <i>Aids</i> , 2015, 29, 1205-1215.	2.2	46
106	A Comparison of Exposure Groups in the EuroSIDA Study: Starting Highly Active Antiretroviral Therapy (HAART), Response to HAART, and Survival. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 1999, 22, 369.	2.1	45
107	Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe. <i>HIV Medicine</i> , 2017, 18, 171-180.	2.2	45
108	Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. <i>Aids</i> , 2008, 22, 367-376.	2.2	43

#	ARTICLE	IF	CITATIONS
109	Severe bacterial non-aids infections in HIV-positive persons: Incidence rates and risk factors. <i>Journal of Infection</i> , 2013, 66, 439-446.	3.3	43
110	Auditing HIV Testing Rates across Europe: Results from the HIDES 2 Study. <i>PLoS ONE</i> , 2015, 10, e0140845.	2.5	43
111	Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years. <i>Archives of Internal Medicine</i> , 2010, 170, 410-419.	3.8	42
112	Dialysis and Renal Transplantation in HIV-Infected Patients: a European Survey. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 55, 582-589.	2.1	42
113	Prognostic Value of Vitamin D Level for All-cause Mortality, and Association With Inflammatory Markers, in HIV-infected Persons. <i>Journal of Infectious Diseases</i> , 2014, 210, 234-243.	4.0	42
114	Assessing the cost-effectiveness of HAART for adults with HIV in England. <i>HIV Medicine</i> , 2001, 2, 52-58.	2.2	41
115	Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 119-127.	9.1	41
116	Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?. <i>Journal of Hepatology</i> , 2013, 59, 213-220.	3.7	41
117	Gender Differences in Virologic Response to Treatment in an HIV-Positive Population: A Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 26, 159-163.	2.1	40
118	Regional Changes Over Time in Initial Virologic Response Rates to Combination Antiretroviral Therapy Across Europe. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2006, 42, 229-237.	2.1	40
119	Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. <i>Aids</i> , 2009, 23, 2199-2208.	2.2	40
120	Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. <i>Aids</i> , 2006, 20, 1141-1150.	2.2	39
121	Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score. <i>Aids</i> , 2007, 21, 1867-1875.	2.2	38
122	The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study. <i>Aids</i> , 2008, 22, 47-56.	2.2	38
123	Biomarkers of impaired renal function. <i>Current Opinion in HIV and AIDS</i> , 2010, 5, 524-530.	3.8	38
124	Multi-drug-resistant tuberculosis in HIV positive patients in Eastern Europe. <i>Journal of Infection</i> , 2014, 68, 259-263.	3.3	38
125	Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. <i>Aids</i> , 2008, 22, 2187-2198.	2.2	37
126	Infection-related and -unrelated malignancies, HIV and the aging population. <i>HIV Medicine</i> , 2016, 17, 590-600.	2.2	37

#	ARTICLE	IF	CITATIONS
127	Reasons for Stopping Antiretrovirals Used in an Initial Highly Active Antiretroviral Regimen: Increased Incidence of Stopping Due to Toxicity or Patient/Physician Choice in Patients with Hepatitis C Coinfection. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 527-536.	1.1	36
128	Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. <i>Aids</i> , 2009, 23, 2485-2495.	2.2	36
129	Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments. <i>Current HIV/AIDS Reports</i> , 2016, 13, 149-157.	3.1	36
130	Highly active antiretroviral therapy and cervical intraepithelial neoplasia. <i>Aids</i> , 2002, 16, 927-929.	2.2	36
131	Long-term exposure to combination antiretroviral therapy and risk of death from specific causes. <i>Aids</i> , 2012, 26, 315-323.	2.2	35
132	Immuno-Virological Discordance and the Risk of Non-AIDS and AIDS Events in a Large Observational Cohort of HIV-Patients in Europe. <i>PLoS ONE</i> , 2014, 9, e87160.	2.5	35
133	Risk of Discontinuation of Nevirapine due to Toxicities in Antiretroviral-Naive and -Experienced HIV-Infected patients with High and Low CD4 ⁺ T-cell Counts. <i>Antiviral Therapy</i> , 2007, 12, 325-334.	1.0	35
134	Cervical Abnormality and Sexually Transmitted Disease Screening in Human Immunodeficiency Virus-Positive Women. <i>Obstetrics and Gynecology</i> , 1997, 89, 71-75.	2.4	34
135	Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens. <i>Aids</i> , 2000, 14, 1717-1720.	2.2	34
136	Causes of death in HIV infection. <i>Aids</i> , 2004, 18, 2333-2337.	2.2	34
137	Advanced chronic kidney disease, end-stage renal disease and renal death among HIV-positive individuals in Europe. <i>HIV Medicine</i> , 2013, 14, 503-508.	2.2	34
138	Prior exposure to thymidine analogs and didanosine is associated with long-lasting alterations in adipose tissue distribution and cardiovascular risk factors. <i>Aids</i> , 2019, 33, 675-683.	2.2	34
139	Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected?. <i>Liver International</i> , 2015, 35, 2384-2391.	3.9	33
140	Regional Differences in AIDS and Non-AIDS Related Mortality in HIV-Positive Individuals across Europe and Argentina: The EuroSIDA Study. <i>PLoS ONE</i> , 2012, 7, e41673.	2.5	32
141	Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?. <i>Aids</i> , 2008, 22, 2381-2390.	2.2	30
142	Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe. <i>European Respiratory Journal</i> , 2014, 43, 166-177.	6.7	30
143	Decline in Esophageal Candidiasis and Use of Antimycotics in European Patients with HIV. <i>American Journal of Gastroenterology</i> , 2005, 100, 1446-1454.	0.4	29
144	A Standardized Algorithm for Determining the Underlying Cause of Death in HIV Infection as AIDS or non-AIDS Related: Results from the EuroSIDA Study. <i>HIV Clinical Trials</i> , 2011, 12, 109-117.	2.0	29

#	ARTICLE	IF	CITATIONS
145	Starting highly active antiretroviral therapy: why, when and response to HAART. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 10-13.	3.0	28
146	Contemporary protease inhibitors and cardiovascular risk. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 8-13.	3.1	28
147	The cardiovascular risk management for people living with HIV in Europe. <i>Aids</i> , 2016, 30, 2505-2518.	2.2	27
148	Changes in AIDS-defining illnesses in a London Clinic, 1987-1998. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 1999, 21, 401-7.	2.1	27
149	Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study. <i>Antiviral Therapy</i> , 2002, 7, 21-30.	1.0	27
150	Effect of Baseline CD4 Cell Counts on the Clinical Significance of Short-Term Immunologic Response to Antiretroviral Therapy in Individuals With Virologic Suppression. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2009, 52, 357-363.	2.1	26
151	Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients. <i>PLoS ONE</i> , 2013, 8, e64283.	2.5	25
152	Deteriorating renal function and clinical outcomes in HIV-positive persons. <i>Aids</i> , 2014, 28, 727-737.	2.2	25
153	Antiviral therapy. <i>Nature</i> , 1995, 375, 195-195.	27.8	24
154	Participation in clinical studies among patients infected with HIV-1 in a single treatment centre over 12 years. <i>HIV Medicine</i> , 2000, 1, 212-218.	2.2	24
155	Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals. <i>Aids</i> , 2018, 32, 1995-2004.	2.2	24
156	The EuroSIDA study: 25 years of scientific achievements. <i>HIV Medicine</i> , 2020, 21, 71-83.	2.2	24
157	Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 83, 240-250.	2.1	24
158	History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change [*] . <i>HIV Medicine</i> , 2010, 11, 469-478.	2.2	23
159	A comparison of estimated glomerular filtration rates using Cockcroft-Gault and the Chronic Kidney Disease Epidemiology Collaboration estimating equations in HIV infection. <i>HIV Medicine</i> , 2014, 15, 144-152.	2.2	23
160	Regional survival differences across Europe In HIV-positive people: the EuroSIDA study. <i>Aids</i> , 1999, 13, 2281-2288.	2.2	22
161	Biomarkers of inflammation, coagulation and microbial translocation in HIV/HCV co-infected patients in the SMART study. <i>Journal of Clinical Virology</i> , 2014, 60, 295-300.	3.1	22
162	Kidney disease in antiretroviral-naïve HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of Antiretroviral Treatment (START) trial. <i>HIV Medicine</i> , 2015, 16, 55-63.	2.2	22

#	ARTICLE	IF	CITATIONS
163	Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. <i>International Journal of Epidemiology</i> , 2017, 46, dyw211.	1.9	22
164	Are Specific Antiretrovirals associated with an Increased Risk of Discontinuation due to Toxicities or Patient/Physician Choice in patients with Hepatitis C Virus Coinfection?. <i>Antiviral Therapy</i> , 2005, 10, 779-790.	1.0	22
165	Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus-infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 650-657.	5.8	21
166	Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz215.	0.9	21
167	Infertility among human immunodeficiency virus-positive women: incidence and treatment dilemmas. <i>Human Reproduction</i> , 1996, 11, 2793-2796.	0.9	20
168	Access to medical care one year prior to diagnosis in 100 HIV-positive women. <i>Family Practice</i> , 1997, 14, 255-257.	1.9	20
169	Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw009.	0.9	20
170	Tuberculosis among HIV-positive patients across Europe. <i>Aids</i> , 2011, 25, 1505-1513.	2.2	19
171	A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study. <i>HIV Medicine</i> , 2011, 12, 259-268.	2.2	19
172	HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective. <i>BMC Infectious Diseases</i> , 2014, 14, S13.	2.9	19
173	Major differences in organization and availability of health care and medicines for HIV/TB coinfecting patients across Europe. <i>HIV Medicine</i> , 2015, 16, 544-552.	2.2	19
174	Major Challenges in Clinical Management of TB/HIV Coinfected Patients in Eastern Europe Compared with Western Europe and Latin America. <i>PLoS ONE</i> , 2015, 10, e0145380.	2.5	19
175	Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 453-460.	2.5	19
176	Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial. <i>PLoS ONE</i> , 2019, 14, e0209911.	2.5	19
177	Changes in AIDS-Defining Illnesses in a London Clinic, 1987-1998. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1999, 21, 401.	0.3	18
178	Clinical Application of Variation in Replication Kinetics During Episodes of Post-transplant Cytomegalovirus Infections. <i>EBioMedicine</i> , 2015, 2, 699-705.	6.1	18
179	Shorter survival in HIV-positive patients with diarrhoea who excrete adenovirus from the GI tract. , 1999, 58, 280-285.		17
180	Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study. <i>PLoS Medicine</i> , 2017, 14, e1002424.	8.4	17

#	ARTICLE	IF	CITATIONS
181	Prevalence and Risk Factors of Moderate-to-Severe Hepatic Steatosis in Human Immunodeficiency Virus Infection: The Copenhagen Co-morbidity Liver Study. <i>Journal of Infectious Diseases</i> , 2020, 222, 1353-1362.	4.0	17
182	Current Hemoglobin Levels Are More Predictive of Disease Progression Than Hemoglobin Measured at Baseline in Patients Receiving Antiretroviral Treatment for HIV Type 1 Infection. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1183-1188.	1.1	16
183	Hyaluronic Acid Levels Predict Increased Risk of Non-Aids Death in Hepatitis-Coinfected Persons Interrupting Antiretroviral Therapy in the Smart Study. <i>Antiviral Therapy</i> , 2011, 16, 667-675.	1.0	16
184	Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy. <i>HIV Medicine</i> , 2013, 14, 370-378.	2.2	16
185	Antiretroviral therapy, immune suppression and renal impairment in HIV-positive persons. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 41-47.	3.8	16
186	Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals. <i>Aids</i> , 2017, 31, 1261-1270.	2.2	16
187	Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-infected treatment-naïve patients. <i>HIV Medicine</i> , 2017, 18, 33-44.	2.2	16
188	Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study. <i>Journal of Infection</i> , 2018, 76, 44-54.	3.3	16
189	Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, e2323-e2333.	5.8	16
190	Two-Year Outcome of a Multidrug Regimen in Patients Who Did Not Respond to a Protease Inhibitor Regimen. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 29, 58-61.	2.1	15
191	Limited but increasing use of treatment for hepatitis C across Europe in patients coinfecting with HIV and hepatitis C. <i>Scandinavian Journal of Infectious Diseases</i> , 2006, 38, 1092-1097.	1.5	15
192	The difficulties of classifying renal disease in HIV-infected patients*. <i>HIV Medicine</i> , 2011, 12, 1-3.	2.2	15
193	Disparities in HIV clinic care across Europe: findings from the EuroSIDA clinic survey. <i>BMC Infectious Diseases</i> , 2016, 16, 335.	2.9	15
194	The EuroSIDA Study: Regional Differences in the HIV-1 Epidemic and Treatment Response to Antiretroviral Therapy among HIV-infected Patients across Europe - A Review of Published Results. <i>Central European Journal of Public Health</i> , 2008, 16, 99-105.	1.1	15
195	Does European or non-European origin influence health care and prognosis for HIV patients in Europe?. <i>HIV Medicine</i> , 1999, 1, 2-9.	2.2	14
196	Age related trends in the incidence of endometrial cancer in South East England 1962-1997. <i>Journal of Obstetrics and Gynaecology</i> , 2005, 25, 35-38.	0.9	14
197	HIV Therapies and the Kidney: Some Good, Some Not So Good?. <i>Current HIV/AIDS Reports</i> , 2012, 9, 111-120.	3.1	14
198	The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people. <i>HIV Medicine</i> , 2018, 19, 90-101.	2.2	14

#	ARTICLE	IF	CITATIONS
199	Classification of death causes after transplantation (CLASS). <i>Medicine (United States)</i> , 2018, 97, e11564.	1.0	14
200	Risk for Non-AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy. <i>Annals of Internal Medicine</i> , 2021, 174, 768-776.	3.9	14
201	Incidence of abacavir hypersensitivity reactions in EuroSIDA. <i>Antiviral Therapy</i> , 2008, 13, 687-696.	1.0	14
202	Regional differences in presentation of AIDS in Europe. <i>Epidemiology and Infection</i> , 2000, 125, 143-151.	2.1	13
203	Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV-infected patients treated with abacavir. <i>HIV Medicine</i> , 2010, 11, 200-208.	2.2	13
204	Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. <i>Aids</i> , 2015, 29, 193-200.	2.2	13
205	Variation in antiretroviral treatment coverage and virological suppression among three HIV key populations. <i>Aids</i> , 2018, 32, 2807-2819.	2.2	13
206	Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe. <i>Aids</i> , 2019, 33, 2013-2024.	2.2	13
207	Calendar Time Trends in the Incidence and Prevalence of Triple-Class Virologic Failure in Antiretroviral Drug-Experienced People With HIV in Europe. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 294-299.	2.1	13
208	Estimated average annual rate of change of CD4+ T-cell counts in patients on combination antiretroviral therapy. <i>Antiviral Therapy</i> , 2010, 15, 563-570.	1.0	12
209	Haemoglobin and Anaemia in the Smart Study. <i>Antiviral Therapy</i> , 2011, 16, 329-337.	1.0	12
210	CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. <i>Aids</i> , 2013, 27, 907-918.	2.2	12
211	MELD score measured day 10 after orthotopic liver transplantation predicts death and re-transplantation within the first year. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1360-1366.	1.5	12
212	Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma. <i>Journal of the National Cancer Institute</i> , 2018, 110, 598-607.	6.3	12
213	Impact of CMV PCR Blips in Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation. <i>Transplantation Direct</i> , 2018, 4, e355.	1.6	12
214	Abdominal Adipose Tissue Is Associated With Alterations in Tryptophan-Kynurenine Metabolism and Markers of Systemic Inflammation in People With Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2019, 221, 419-427.	4.0	12
215	Persistent disparities in antiretroviral treatment (ART) coverage and virological suppression across Europe, 2004 to 2015. <i>Eurosurveillance</i> , 2018, 23, .	7.0	12
216	Virological Failure among Patients on Haart from across Europe: Results from the EuroSIDA Study. <i>Antiviral Therapy</i> , 2000, 5, 107-112.	1.0	12

#	ARTICLE	IF	CITATIONS
217	The relationship between beta-2-microglobulin, CD4 lymphocyte count, AIDS and death in HIV-positive individuals. <i>Epidemiology and Infection</i> , 1997, 118, 259-266.	2.1	11
218	A practical approach to adjusting for attrition bias in HIV clinical trials with serial marker responses. <i>Aids</i> , 1998, 12, 1155-1161.	2.2	11
219	Insurability of HIV-positive people treated with antiretroviral therapy in Europe. <i>Aids</i> , 2013, 27, 1641-1655.	2.2	11
220	Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis. <i>Aids</i> , 2014, 28, 577-587.	2.2	11
221	Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study. <i>HIV Medicine</i> , 2015, 16, 533-543.	2.2	11
222	Patterns in the incidence of age-related ovarian cancer in South East England 1967-1996. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2000, 107, 1094-1096.	2.3	10
223	Changes in AIDS-Defining Illnesses in a London Clinic, 1987-1998. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 2006, 21, 401.	0.3	10
224	The Clinical Benefits of Antiretroviral Therapy in Severely Immunocompromised HIV-1-Infected Patients with and without Complete Viral Suppression. <i>Antiviral Therapy</i> , 2012, 17, 1291-1300.	1.0	10
225	TB Meningitis in HIV-Positive Patients in Europe and Argentina: Clinical Outcome and Factors Associated with Mortality. <i>BioMed Research International</i> , 2013, 2013, 1-9.	1.9	10
226	Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study. <i>BMC Nephrology</i> , 2014, 15, 51.	1.8	10
227	Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals. <i>Aids</i> , 2016, 30, 1583-1596.	2.2	10
228	Associations between HIV-RNA-based indicators and virological and clinical outcomes. <i>Aids</i> , 2016, 30, 1961-1972.	2.2	10
229	Independent Association of Interleukin 6 With Low Dynamic Lung Function and Airflow Limitation in Well-Treated People With Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2021, 223, 1690-1698.	4.0	10
230	Changing treatment patterns among patients with HIV: Royal Free Hospital 1987-97. <i>HIV Medicine</i> , 1999, 1, 32-39.	2.2	9
231	Two-Year Outcome of a Multidrug Regimen in Patients Who Did Not Respond to a Protease Inhibitor Regimen. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 29, 58-61.	2.1	9
232	Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999. <i>HIV Medicine</i> , 2008, 9, 41-46.	2.2	9
233	Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study. <i>BMC Infectious Diseases</i> , 2012, 12, 229.	2.9	9
234	Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease. <i>Aids</i> , 2014, 28, 2565-2571.	2.2	9

#	ARTICLE	IF	CITATIONS
235	Long-lasting alterations in adipose tissue density and adiponectin production in people living with HIV after thymidine analogues exposure. <i>BMC Infectious Diseases</i> , 2019, 19, 708.	2.9	9
236	Clinical outcomes in persons coinfected with HIV and HCV: Impact of HCV treatment. <i>Clinical Infectious Diseases</i> , 2020, 70, 2131-2140.	5.8	9
237	Establishing a hepatitis C continuum of care among <sc>HIV</sc>/hepatitis C virus coinfected individuals in Euro<sc>SIDA</sc>. <i>HIV Medicine</i> , 2019, 20, 264-273.	2.2	9
238	Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral naïve persons starting treatment. <i>HIV Medicine</i> , 2020, 21, 599-606.	2.2	9
239	Delayed diagnosis of tuberculosis in persons living with HIV in Eastern Europe: associated factors and effect on mortality—a multicentre prospective cohort study. <i>BMC Infectious Diseases</i> , 2021, 21, 1038.	2.9	9
240	Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir. <i>Aids</i> , 2001, 15, 999-1008.	2.2	8
241	The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era. <i>Clinical Trials</i> , 2006, 3, 119-132.	1.6	8
242	Analysis of the incidence and mortality of vulval cancer in women in South East England 1960–1999. <i>Archives of Gynecology and Obstetrics</i> , 2009, 279, 113-117.	1.7	8
243	European <sc>AIDS</sc> Clinical Society Standard of Care meeting on <sc>HIV</sc> and related coinfections: The Rome Statements. <i>HIV Medicine</i> , 2016, 17, 445-452.	2.2	8
244	Predictive Value of Prostate Specific Antigen in a European HIV-positive Cohort: Does One Size Fit All?. <i>Antiviral Therapy</i> , 2016, 21, 529-534.	1.0	8
245	Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. <i>Journal of Infectious Diseases</i> , 2019, 220, 1629-1634.	4.0	8
246	No need for secondary <i>Pneumocystis jirovecii</i> pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/μL. <i>Journal of the International AIDS Society</i> , 2021, 24, e25726.	3.0	8
247	The hepatitis C cascade of care in HIV/hepatitis C virus coinfected individuals in Europe: regional and intra-regional differences. <i>Aids</i> , 2022, 36, 423-435.	2.2	8
248	Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. <i>PLoS ONE</i> , 2020, 15, e0243625.	2.5	8
249	Predictors of CD4+ T-Cell Counts of HIV Type 1 Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. <i>Journal of Infectious Diseases</i> , 2013, 207, 759-767.	4.0	7
250	Prevalence of impaired renal function in virologically suppressed people living with HIV compared with controls: the Copenhagen Comorbidity in HIV Infection (COCOMO) study*. <i>HIV Medicine</i> , 2019, 20, 639-647.	2.2	7
251	Serious clinical events in HIV-positive persons with chronic kidney disease. <i>Aids</i> , 2019, 33, 2173-2188.	2.2	7
252	Independent Associations of Tumor Necrosis Factor-Alpha and Interleukin-1 Beta With Radiographic Emphysema in People Living With HIV. <i>Frontiers in Immunology</i> , 2021, 12, 668113.	4.8	7

#	ARTICLE	IF	CITATIONS
253	Improving healthcare for patients with HIV, tuberculosis and hepatitis C in eastern Europe: a review of current challenges and important next steps. <i>HIV Medicine</i> , 2022, 23, 48-59.	2.2	7
254	HIV Survival Benefit Associated with Earlier Antiviral Therapy. <i>Annals of Internal Medicine</i> , 2004, 140, 578.	3.9	7
255	Baseline Resistance and Virological Outcome in Patients with Virological Failure who Start a Regimen Containing Abacavir: EuroSIDA Study. <i>Antiviral Therapy</i> , 2004, 9, 787-800.	1.0	7
256	Cofactors and markers of disease progression in human immunodeficiency virus infection. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 1998, 161, 177-189.	1.1	6
257	Comparison of Single and Boosted Protease Inhibitor Versus Nonnucleoside Reverse Transcriptase Inhibitor-containing cART Regimens in Antiretroviral-Naïve Patients Starting cART After January 1, 2000. <i>HIV Clinical Trials</i> , 2006, 7, 271-284.	2.0	6
258	Incidence of pancreatitis in HIV-infected patients, and the association with antiretroviral therapy. <i>Aids</i> , 2008, 22, 997-998.	2.2	6
259	Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens. <i>HIV Medicine</i> , 2018, 19, 102-117.	2.2	6
260	The Impact of Immunosuppression on Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: The D:A:D Study. <i>Journal of Infectious Diseases</i> , 2021, 223, 632-637.	4.0	6
261	Healthcare delivery for HIV-positive people with tuberculosis in Europe. <i>HIV Medicine</i> , 2021, 22, 283-293.	2.2	6
262	Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naïve and -experienced HIV-infected patients with high and low CD4+ T-cell counts. <i>Antiviral Therapy</i> , 2007, 12, 325-33.	1.0	6
263	Uptake of Tenofovir-Based Antiretroviral Therapy among HIV-HBV-Coinfected Patients in the EuroSIDA Study. <i>Antiviral Therapy</i> , 2018, 23, 405-413.	1.0	5
264	Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?. <i>Aids</i> , 2018, 32, 205-215.	2.2	5
265	Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin America. <i>BMC Infectious Diseases</i> , 2018, 18, 191.	2.9	5
266	Virological failure among patients on HAART from across Europe: results from the EuroSIDA study. <i>Antiviral Therapy</i> , 2000, 5, 107-12.	1.0	5
267	Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?. <i>Antiviral Therapy</i> , 2005, 10, 779-90.	1.0	5
268	Active drug injecting and progression of HIV infection. <i>Aids</i> , 1994, 8, 385-386.	2.2	4
269	Survival after a very low (< 5 Å– 106/l) CD4+ T-cell count in individuals infected with HIV. <i>Aids</i> , 1997, 11, 1123-1127.	2.2	4
270	Use of Risk Equations for Predicting Disease Progression in HIV Infection. <i>Clinical Infectious Diseases</i> , 2009, 48, 951-953.	5.8	4

#	ARTICLE	IF	CITATIONS
271	High rate of hepatitis C virus (HCV) recurrence in HIV-infected individuals with spontaneous HCV RNA clearance. <i>HIV Medicine</i> , 2014, 15, n/a-n/a.	2.2	4
272	A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. <i>Infection</i> , 2014, 42, 757-762.	4.7	4
273	Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe. <i>HIV Medicine</i> , 2018, 19, 324-338.	2.2	4
274	Prevalence and outcomes of pregnancies in women with HIV over a 20-year period. <i>Aids</i> , 2021, 35, 2025-2033.	2.2	4
275	Do women with HIV infection consult with their GPs?. <i>British Journal of General Practice</i> , 1998, 48, 1329-30.	1.4	4
276	HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe. <i>HIV Medicine</i> , 2022, 23, 684-692.	2.2	4
277	Late presentation to HIV/AIDS testing, treatment or continued care: clarifying the use of CD4 evaluation in the consensus definition. <i>HIV Medicine</i> , 2014, 15, 129-129.	2.2	3
278	Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2021, 86, 248-257.	2.1	3
279	Mortality and cause of death in persons with chronic hepatitis B virus infection versus healthy persons from the general population in Denmark. <i>Journal of Viral Hepatitis</i> , 2022, 29, 727-736.	2.0	3
280	Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/ μ l in the era of cART. <i>Scandinavian Journal of Infectious Diseases</i> , 2008, 40, 908-913.	1.5	2
281	Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. <i>Journal of the International AIDS Society</i> , 2010, 13, O43.	3.0	2
282	Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort. <i>HIV Medicine</i> , 2018, 19, 252-260.	2.2	2
283	Ritonavir-Boosted Protease Inhibitors Do Not Significantly Affect the Performance of Creatinine-Based Estimates of GFR. <i>Kidney International Reports</i> , 2020, 5, 734-737.	0.8	2
284	Impact of Kaposi's sarcoma on HIV disease progression. <i>Aids</i> , 1999, 13, 286.	2.2	2
285	The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study. <i>HIV Medicine</i> , 2022, 23, 585-598.	2.2	2
286	The use of CD4 counts as prognostic markers in HIV infection. <i>Aids</i> , 1995, 9, 1205-1206.	2.2	1
287	Percentage of CD4 Lymphocytes and Risk of AIDS. <i>JAMA - Journal of the American Medical Association</i> , 1995, 274, 1836.	7.4	1
288	Serum HIV-1 RNA and routine patient monitoring. <i>Lancet</i> , The, 1995, 345, 1441-1442.	13.7	1

#	ARTICLE	IF	CITATIONS
289	Changes in Lymphocyte Subsets in Human Immunodeficiency Virus-Positive Persons with ≤ 5 CD4 T Lymphocytes/mm ³ . <i>Journal of Infectious Diseases</i> , 1998, 178, 1166-1169.	4.0	1
290	Continuation of hormone replacement therapy after hysterectomy. <i>Climacteric</i> , 2003, 6, 58-66.	2.4	1
291	Clinical outcomes in clinical trials of anti-HIV treatment. <i>Future HIV Therapy</i> , 2007, 1, 251-258.	0.4	1
292	Reply to Pascual Pareja et al.. <i>Journal of Infectious Diseases</i> , 2009, 199, 1557-1557.	4.0	1
293	411 HEPATITIS C VIRUS REAPPEARANCE IN HIV-INFECTED PATIENTS WITH SPONTANEOUS HCV-RNA CLEARANCE. <i>Journal of Hepatology</i> , 2009, 50, S155.	3.7	1
294	The prevalence and predictive value of dipstick urine protein in HIV-positive persons in Europe. <i>Journal of the International AIDS Society</i> , 2014, 17, 19561.	3.0	1
295	The benefits and risks of PrEP and kidney function. <i>Lancet HIV</i> , 2016, 3, e501-e502.	4.7	1
296	Cross-Sectional Studies in AIDS Pathogenesis. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1997, 14, 153-157.	0.3	1
297	Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa470.	0.9	1
298	A pilot study to determine the prevalence of HIV in persons presenting for care with selected conditions: preliminary results from the HIV in Europe study. <i>Journal of the International AIDS Society</i> , 2010, 13, O16.	3.0	0
299	Haemoglobin and anaemia in the SMART study. <i>Journal of the International AIDS Society</i> , 2010, 13, P144.	3.0	0
300	Changing antiretrovirals whilst viral load < 50 copies/ml and relationship with CD4 count changes. <i>Journal of the International AIDS Society</i> , 2010, 13, P24.	3.0	0
301	Chronic kidney disease in patients with normal eGFR at baseline: results from EuroSIDA. <i>Journal of the International AIDS Society</i> , 2010, 13, P82.	3.0	0
302	Elevation in Liver Transaminase (ALT-flares) in Transplant (TX) Recipients: Risk factors and Consequences. <i>Open Forum Infectious Diseases</i> , 2014, 1, S26-S26.	0.9	0
303	Thrombocytopenia and cancer risk during HIV infection. <i>Aids</i> , 2015, 29, 1425-1427.	2.2	0
304	Continuation of hormone replacement therapy after hysterectomy. <i>Climacteric</i> , 2003, 6, 58-66.	2.4	0